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The G-protein linked signaling system (GPLS) comprises a large number of G-proteins, G
protein-coupled receptors (GPCRs), GPCR ligands, and downstream effector molecules.
G-proteins interact with both GPCRs and downstream effectors such as cyclic adenosine
monophosphate (cAMP), phosphatidylinositols, and ion channels. The GPLS is implicated
in the pathophysiology and pharmacology of both major depressive disorder (MDD) and
bipolar disorder (BPD). This study evaluated whether GPLS is altered at the transcript
level. The gene expression in the dorsolateral prefrontal (DLPFC) and anterior cingulate
(ACC) were compared from MDD, BPD, and control subjects using Affymetrix Gene Chips
and real time quantitative PCR. High quality brain tissue was used in the study to control
for confounding effects of agonal events, tissue pH, RNA integrity, gender, and age.
GPLS signaling transcripts were altered especially in the ACC of BPD and MDD subjects.
Transcript levels of molecules which repress cAMP activity were increased in BPD
and decreased in MDD. Two orphan GPCRs, GPRC5B and GPR37, showed significantly
decreased expression levels in MDD, and significantly increased expression levels in
BPD. Our results suggest opposite changes in BPD and MDD in the GPLS, “activated”
cAMP signaling activity in BPD and “blunted” cAMP signaling activity in MDD. GPRC5B
and GPR37 both appear to have behavioral effects, and are also candidate genes for
neurodegenerative disorders. In the context of the opposite changes observed in BPD
and MDD, these GPCRs warrant further study of their brain effects.
Keywords: G-protein coupled receptor (GPCR), transcriptome, bipolar disorder, major depressive disorder, GPR37,
GPRC5B, cyclic AMP, phosphatidylinositol
INTRODUCTION
The G-protein linked signaling system (GPLS) comprises G-
proteins, G protein-coupled receptors (GPCRs), GPCR ligands,
and downstream effector molecules. G-proteins interact with
both GPCRs and downstream effectors such as cyclic adenosine
monophosphate (cAMP), phosphatidylinositols, and ion chan-
nels. The GPLS is implicated in the pathophysiology and phar-
macology of both major depressive disorder (MDD) and bipolar
disorder (BPD). GPCRs are integral membrane proteins with key
roles in numerous physiological cellular processes. GPCRs can
signal ligand binding events by conformational changes that acti-
vate intracellular G proteins. Active G proteins in turn trigger
intracellular downstream signaling pathways. Evidence suggests
that altered GPCRs and their two major downstream signaling
pathways, mediated by effectors such as cAMP and phosphatidyli-
nositol, may be involved in the pathophysiology of BPD and
MDD as well as in the mechanism of drug treatment for these
disorders. Altered immunoreactivities and functional activities of
proteins related to cAMP signaling pathways have been reported
in the brain and peripheral blood cells of BPD patients (Jope
et al., 1996; Karege et al., 1996; Gould and Manji, 2002; Chang
et al., 2003). Also, mood stabilizers and antidepressants have been
shown to affect cAMP and phosphatidylinositol signaling (Donati
and Rasenick, 2003; Harwood, 2005; Xu et al., 2007; Racagni and
Popoli, 2008). There are at least 210 GPCRs for which a nat-
ural ligand has been identified. There are 150 orphan GPCRs,
with no known ligand or function (Wise et al., 2004), that might
be relevant to downstream signaling dysregulation observed in
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BPD and MDD. Among the signal transmission systems associ-
ated with GPCRs, monoaminergic, and neuropeptidergic systems
are believed to be dysregulated in BPD and MDD (Lieb et al.,
2002; Elhwuegi, 2004; Carvajal et al., 2006; Ruhe et al., 2007).
Messenger RNA expression levels of a number of GPCRs,
their ligands, and effector molecules involved in the GPLS path-
ways have been measured in post-mortem brains of BPD and
MDD patients (Young et al., 1996; Spleiss et al., 1998; Caberlotto
and Hurd, 2001; Kuromitsu et al., 2001; Zhou et al., 2001;
Gurevich et al., 2002; Pandey et al., 2002; Agam et al., 2003;
Chang et al., 2003; Dwivedi et al., 2004; Escriba et al., 2004;
Lopez-Figueroa et al., 2004; Sherrin et al., 2004). Brain imag-
ing studies have implicated anterior cingulate cortex (ACC) and
the dorsolateral prefrontal cortex (DLPFC) in the pathophysi-
ology of mood disorders (Harrison, 2002; Rogers et al., 2004;
Frazier et al., 2005). In this study, the DLPFC and ACC were
selected for microarray gene expression profiling of BPD and
MDD patients focusing on the involvement of genes involved
in GPLS pathways in these disorders and the effect of drug
treatments. These cortical regions were selected because of the
integral role of the ACC and DLPFC in the control of impulses,
memory, learning, and hedonic evaluation, and depression. This
study compares an a priori set of genes, in both mood dis-
orders, using two cortical regions. There have been a number
of previous studies comparing MDD and BPD by microarray
analysis to controls, e.g., studies involving samples from the
Stanley Foundation Neuropathology Brain collection (Kim and
Webster, 2010). However, few studies have analyzed gene expres-
sion by microarray analysis of the Anterior Cingulate in both
mood disorder groups, aside from studies involving the Pritzker
Neuropsychiatric Disorders papers which involved selected path-
ways of glutamate, mitochondria, and growth factors (Evans et al.,
2004; Choudary et al., 2005; Vawter et al., 2006). We hypothe-
sized that there would be dysregulation of the GPLS in bothmood
disorders compared to controls, and that some overlap between
the signature of each mood disorder would be found, given that
most of our subjects were in a depressive state near the time of
death.
MATERIALS AND METHODS
SUBJECTS
The primary cohort consisted of 22 subjects, including seven
healthy controls, six patients with bipolar disorder type I (BPD),
and nine patients with MDD (Cohort A). The MDD results
were validated with an additional independent cohort, includ-
ing seven controls and five MDD patients (Cohort B). Toxicology
data and/or recent clinical data were examined for the BPD and
MDD subjects and detailed clinical information is summarized
in Table 1. To minimize potential confounding effects of agonal
events, we used three criteria in subject selection: brain tissue
pH of >6.6, ribosomal RNA 28S/18S ratio of >1.5, and sudden
death with the agonal period lasting less than 1 h. We have pre-
viously found large differences in gene expression values when
using longer agonal periods, >1 h and as long as 1–2 days, and
would have found large effects due only to mixing samples with
long and short agonal duration (Li et al., 2004; Tomita et al., 2004;
Vawter et al., 2006; Atz et al., 2007).
Brain tissue and clinical information were obtained by the UCI
Brain Bank staff with the informed consent of decedents’ next-of-
kin, and were processed through a standard protocol approved by
the local UCI Institutional Review Board (Tomita et al., 2004).
None of the subjects included in this study had specific ago-
nal conditions including cancer, hypoxia, coma, pyrexia, seizure,
dehydration, hypoglycemia, multi-organ failure, skull fracture,
ingestion of neurotoxic substances or prolonged agonal duration,
which are known to affect tissue pH, RNA integrity and gene
expression profiles in post-mortem brain (Li et al., 2004; Tomita
et al., 2004). The variables for gender, age, post-mortem interval
(PMI), tissue pH, and 28S/18S ratio were balanced between diag-
nostic and control groups. Patients who were prescribed lithium
and selective serotonin reuptake inhibitor (SSRI) at the time of
death are also indicated (Table 1).
MICROARRAY GENE EXPRESSION
The experimental procedures are described elsewhere (Evans
et al., 2004; Tomita et al., 2004). Total RNA was extracted from
ACC and DLPFC of Cohort A (Table 1), and purified with silica-
based mini-spin columns (Qiagen, Valencia, California). The
oligonucleotide microarray experiments were conducted utiliz-
ing Affymetrix U133A Gene Chips following the manufacturer’s
protocol (Affymetrix, Santa Clara, CA). To detect gene expres-
sion differences between diagnostic groups reliably, we replicated
the experiments as follows: Cohort A used 22 subjects’ total RNA
fromACCwhich were processed at two laboratories (University of
California, Irvine andUniversity of California, Davis) andDLPFC
that were processed independently (University of California,
Davis and University of Michigan, Ann Arbor). For Cohort B 12
total RNA samples from ACC and DLPFC (additional 12 sub-
jects) were processed at the same independent laboratories as
cohort A. In summary, for each BPD subject there were dupli-
cate arrays run, and for MDD subjects there were duplicate arrays
run, plus an additional cohort of MDD subjects were run also
with duplicate arrays.
DATA ANALYSES
Since a considerable number of probe sequences in the
Affymetrix original chip definition file (CDF) were found
to incorrectly BLAST to other transcripts, a refined CDF
based on an UniGene cluster was developed (Evans et al.,
2004; Dai et al., 2005), and was used for data analyses pre-
sented in this paper. The refined CDF file is available on
http://brainarray.mhri.med.umich.edu/brainarray/.
The focus of this study was 445 GPLS genes found on the
Affymetrix arrays used in this study (Table S1). Signal intensities
were extracted with Robust Multi-array Average (RMA) for each
probe set and each subject. Gene-wise Pearson’s correlation coef-
ficients between experimental duplicates were calculated. Only
the genes that were significantly correlated (p < 0.05) between
experimental duplicates were considered to be reliably measured
genes, and were subjected to downstream analyses. These genes
were analyzed in a mixed-model ANOVA utilizing Partek Pro
6.0 (Partek, MO) for the main effect of the diagnostic classifi-
cation (BPD, MDD, control) and for sex (Evans et al., 2004).
We calculated the false discovery rate (FDR) in the microarray
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Table 1 | Demographics of two cohorts with mood disorder and matched controls, Cohorts A and B.
Gender (L)a Age Diagnosis PMI pH 28S/18S SSRIb Manner of death Medications, time of death
COHORT A (BPD, MDD, CONTROL)
Male 9 BPD 11.25 6.91 1.55 NP Exsanguination rupture of aorta
Male (L) 3 BPD 9 7.12 2.1 NP Hanging Mood Stabilizer, Antipsychotic,
Anticholinergic
Male (L) 26 BPD 19 6.92 1.81 NP Carbon monoxide poisoning Antipsychotic, Mood Stabilizer,
Mood Stabilizer, Antianxiety
Agent, Anticholinergic
Female 56 BPD 29 6.83 2.17 SSRI+ Acute strychnine intoxication Antidepressant-Atyp#,
Antidepressant-HCA#,
Antianxiety Agent, Hypnotic,
Antidepressant-SSRI
Male 52 BPD 28 7.05 2.36 NP Acute hemorrhage slash wound to
neck
Male (L) 59 BPD 15.5 6.99 1.58 NP Myocardial infarction Mood Stabilizer
Female 72 MDD 21 7.13 2.28 NP Pulmonary edema due to acute
intoxication
Hypnotic, Antianxiety Agent,
Antianxiety Agent,
Antidepressant-HCA,
Antidepressant-HCA
Male 19 MDD 18 7.11 2.17 NP Asphyxiation due to hanging
Male 58 MDD 24 6.93 2.26 SSRI+ Hanging Antidepressant-SSRI,
Antidepressant-Atyp
Male 49 MDD 31 7 1.96 SSRI+ Accidental overdose of propoxyphene,
norpropoxyphene, amitriptyline,
nortriptyline, sertaline, norsertaline
and zolpidem
Antidepressant-SSRI, Antianxiety
Agent, Hypnotic,
Antidepressant-HCA
Male 46 MDD 27 6.91 2.07 NP Occlusion of left anterior descending
coronary artery
Hypnotic, Antianxiety Agent,
Antianxiety Agent
Male 49 MDD 27 7.19 2.24 NP Hanging
Male 52 MDD 16 6.82 1.82 SSRI+ Acute myocardial infarction Antidepressant-SSRI,
Antidepressant-Atyp,
Antipsychotic, Hypnotic
Female 48 MDD 37 6.95 1.86 SSRI+ Overdose morphine Anticonvulsant,
Antidepressant-SSRI, Antianxiety
Agent
Male 39 MDD 27.5 6.79 1.77 SSRI+ Hanging Anticonvulsant,
Antidepressant-SSRI
Female 60 Control 24 6.99 1.77 NA Myocardial infarction
Male 70 Control 27 7.03 1.89 NA Myocardial infarction
Male 18 Control 22 6.97 2.53 NA Freshwater drowning
Male 58 Control 26 7.02 1.99 NA Ventricular fibrillation
Male 55 Control 18 6.89 2.2 NA Myocardial infarction
Male 45 Control 21 6.86 1.92 NA Congestive heart failure
Male 44 Control 23 6.87 1.9 NA Myocardial infarction
COHORT B (MDD, CONTROL)
Male 35 MDD 24.75 7.04 2.14 NP Hanging Antidepressant-Atyp#
Male 47 MDD 29 7.25 2.08 NP Hanging
Female 80 MDD 15 6.68 2.21 NP Hypertrophic cardiomyopathy
Male 63 MDD 28.5 7.17 1.57 NP Ruptured aortic abdominal aneurysm
Male 66 MDD 32 7.05 2.07 SSRI+ Cardiac event Antidepressant-SSRI
Male 77 Control 7.25 6.62 2.16 NA Cardiac event
Male 39 Control 18 6.81 1.67 NA Cardiac arrhythmia
Male 39 Control 30 7.02 1.88 NA Electrocution
(Continued)
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Table 1 | Continued
Gender (L)a Age Diagnosis PMI pH 28S/18S SSRIb Manner of death Medications, time of death
Male 41 Control 22.5 7.01 2.08 NA Severe coronary arteriosclerosis
Male 65 Control 13.5 6.88 2.05 NA Hemorrhagic pericarditis
Male 49 Control 27.5 6.68 1.68 NA Coronary Insufficiency
Female 45 Control 32 6.6 1.71 NA Bilateral extensive pulmonary
embolism
aL, prescribed lithium at time of death.
#Antidepressant-Atypical, Antidepressant-heterocyclic.
Mean + standard deviation of age: BPD, 47.5 ± 18.7; MDD, 48.0 ± 14.2; control, 50 ± 16.7.
Mean + standard deviation of PMI: BPD, 18.6 ± 8.4; MDD, 25.4 ± 6.5; control, 23.0 ± 3.1.
Mean + standard deviation of pH: BPD, 7.0 ± 0.1; MDD, 7.0 ± 0.1; control, 6.9 ± 0.1.
Mean + standard deviation of 28S/18S: BPD, 1.9 ± 0.3; MDD, 2.0 ± 0.2; control, 2.0 ± 0.3.
Mean ± standard deviation of age: MDD, 58.2 ± 17.5; control, 50.7 ± 14.7.
Mean ± standard deviation of PMI: MDD, 25.9 ± 6.6; control, 21.5 ± 9.1.
Mean ± standard deviation of pH: MDD, 7.0 ± 0.2; control, 6.8 ± 0.2.
Mean ± standard deviation of 28S/18S: MDD, 2.0 ± 0.3; control, 1.9 ± 0.2.
bNP, not prescribed SSRI; NA, not applicable for SSRI.
study by Benjamini-Hochberg step-down procedure using Partek
Genomics setting the FDR to 0.05. Since the three diagnostic
groups were well matched on age and pH (Table 1), the gene
expression values were not tested by ANCOVA. However, in post-
hoc analysis, we determined whether the tissue pH was correlated
with any differentially expressed GPLS genes. The post-hoc analy-
sis showed that there were no significant correlations found with
tissue pH and differentially expressed GPLS genes. A post-hoc
group comparison of subjects with SSRI treatment and without
treatment was conducted in MDD subjects, and similar analysis
for lithium was conducted for BPD subjects.
The hypergeometric distribution was used for calculating
probabilities that the observed number of genes in each gene
category for cAMP or PI signaling pathways (listed in Table S2)
were detected as differentially expressed genes in the compar-
isons between patients and control. False discovery rate were
evaluated byQVALUE (Storey and Tibshirani, 2003). Calculations
for hypergeometric probabilities were performed using SISA
online statistics package (http://www.quantitativeskills.com/sisa/
distributions/hypergeo.htm).
QUANTITATIVE PCR
For further technical evaluation of the microarray data, we eval-
uated mRNA expression levels by quantitative real-time reverse
transcriptase PCR (qPCR) for the seven genes listed in Table 3.
We followed up on results primarily that met FDR in cohort
A for BPD, and both Cohorts A and B for MDD, except for
RGS20, which we followed up based upon Cohort A only. These
genes selected for qPCR analyses met the criteria of FDR at
the level of accepting 5% false positives and percentage change
greater than 20% in the ACC microarray results. The thresh-
old cycle (Ct) values for the target transcripts were normalized
to averaged Ct values for two reference transcripts, Jagged 1
(JAG1) and solute carrier family 9 isoform 1 (SLC9A1), which
showed equivalent expression levels among the three diagnos-
tic groups (BPD, MDD, and control) throughout the 3 brain
regions on our normalized microarray data. After DNase diges-
tion and purification, total RNA (1µg) samples from each of
the 34 subjects in Cohorts A and B were used as a template for
first-strand cDNA synthesis using poly-dT primer. The mRNA
for each transcript was measured using the SybrGreen system
with Prism model 7000-sequence detection instrument (Applied
Biosystems, Foster City, California) and primer sequences listed
in Table S1. The Ct , which correlatedinversely with the target
mRNA concentration, was measured as the cycle number at
which the SybrGreen fluorescent signal increased abovea pre-set
threshold level. The qPCR experiments were performed three
times for each transcript, and the Ct triplicate values were
averaged.
In situ HYBRIDIZATION
The gene expression fold changes for GPRC5B and GPR37
showed an increase in BPD and decrease in MDD. We selected
those genes for in situ hybridization (ISH) using the ACC regions
from six representative subjects to evaluate the cellular local-
ization of GPRC5B and GPR37 mRNA expression. A formal
statistical analysis of the ISH data was not applied due to low sub-
ject number. ISHwas performed following a protocol as described
elsewhere (Neal et al., 2001; Lopez-Figueroa et al., 2004). Briefly,
frozen ACC tissue blocks were cut into 12-µm sections on a
cryostat. After fixation with 4% paraformaldehyde for 1 h, sec-
tions were hybridized overnight with a 35S-labeled antisense
cRNA probes for GPRC5B and GPR37. Following hybridization,
wash, RNase A treatment, dehydration and air-dry, sections were
exposed to Kodak XAR-5 X-ray film for 21 days. Technical con-
trol studies were performed by (1) using 35S-labeled sense RNA
probes for GPRC5B and GPR37, and (2) pre-treating tissue with
RNase A before hybridizing with the antisense probes.
RESULTS
Significantly dysregulated GPLS genes that passed FDR (p <
0.05) in either Cohort A or B and either mood disorder, BPD
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or MDD, are listed in Table 2. For completeness, the uncorrected
p-values are also shown, as some genes only met FDR for a sin-
gle comparison. In general, equal numbers of GPLS genes passed
FDR in BPD and MDD in the ACC (10 genes for BPD and 10
genes for MDD that passed FDR), compared with DLPFC (1 gene
for BPD and 5 genes for MDD). Thus, about three fold more
gene expression differences in mood disorder were found in the
ACC showed compared to the DLPFC. The genes in Table 2 also
showed non-significant correlations between gene expression and
tissue pH (all p-values > 0.1) suggesting that residual pH-agonal
effects on the expression levels of GPCR genes did not remain in
the data set, even though complete elimination of these factors
may not be possible with matching of subject’s age and pH, and
inclusion of subjects that had rapid deaths.
CYCLIC AMP SIGNALING PATHWAY
The genes involved in cAMP signaling pathways, which were
differentially expressed in ACC of BPD patients compared to
controls, are listed in Table 2. The cAMP signaling pathway is
shown in Figure 1A. The data show that six significant tran-
scripts out of 39 that repress cAMP signaling activity (Table 1)
were increased in ACC from BPD patients at the transcriptional
level. The group of molecules that act negatively on cAMP sig-
naling activity was significantly over-represented in BPD based
on a hypergeometric distribution (p = 0.037, q = 0.36). Thus,
there was a nominal enrichment of genes that act negatively on
cAMP signaling activity (Gi proteins, phosphodiesterase, pro-
tein kinase A inhibitors, and protein phosphatase) in BPD in
the ACC.
Table 2 | GPLS genes significantly dysregulated in anterior cingulate cortex by microarray.
Category Anterior Cingulate Cortex
Symbol BPD Cohort A MDD Cohort A MDD Cohort B
% change Unadjusted
p-value
FDR % change Unadjusted
p-value
FDR % change
Unadjusted
p-value
FDR
A. Cyclic AMP
signaling pathway
NPY1R 24.4 0.000889 p < 0.05 21.9 0.000855 p < 0.05 −17.7 0.02108
NPY 33.0 1.48E−06 p < 0.05 3.6 0.37116 3.6 0.54313
SST 22.1 5.4E−05 p < 0.05 −13.3 0.002288 p < 0.05 −6.5 0.10886
GRM3 34.4 0.000113 p < 0.05 −10.9 0.081528 −17.9 0.01528
EDG1 −4.1 0.194276 −21.2 5.44E−07 p < 0.05 −10.4 0.00180
EDG2 18.2 0.000195 p < 0.05 4.8 0.1806 −4.5 0.22364
GNAI1 40.4 0.000289 p < 0.05 −2.4 0.740184 −9.0 0.26898
RGS20 15.6 0.005655 p < 0.05 −29.2 5.85E−06 p < 0.05 −13.9 0.00992
PDE1A 24.1 0.000599 p < 0.05 14.4 0.01141 p < 0.05 −8.0 0.19030
PDE8A 12.5 0.004505 p < 0.05 −23.1 3.96E−06 p < 0.05 −17.8 0.00138
PKIA 16.6 0.001318 p < 0.05 9.4 0.025332 −1.2 0.82836
PPP1CA 16.8 3.61E−06 p < 0.05 1.1 0.627546 1.1 0.79955
PPP1R3C −15.4 0.000544 p < 0.05 −63.2 6.98E−13 p < 0.05 −21.4 0.00006 p < 0.05
B. Phosphatidylinositol
signaling pathway
NTSR2 −1.4 0.741755 −18.6 0.000195 p < 0.05 −24.7 0.00012 p < 0.05
EDNRB −1.0 0.765956 −31.2 1.9E−08 p < 0.05 −15.9 0.00070 p < 0.05
EDG2 18.2 0.000195 p < 0.05 4.8 0.1806 −4.5 0.22364
INPP5F 16.2 0.002445 p < 0.05 21.8 6.25E−05 p < 0.05 8.0 0.30847
ITPKB 11.5 0.035537 −12.3 0.015197 p < 0.05 −34.0 0.00010 p < 0.05
INPP1 24.9 9.4E−06 p < 0.05 −1.1 0.761718 −7.4 0.04372
PIK3C2A 22.3 0.020892 p < 0.05 −35.9 0.000393 p < 0.05 −13.1 0.15764
PIK3C2B 14.8 0.001516 p < 0.05 −11.1 0.005757 p < 0.05 −1.1 0.81543
ITPR1 5.5 0.123943 17.4 2.66E−05 p < 0.05 10.5 0.15830
PRKCB1 −0.5 0.886704 11.5 0.00341 p < 0.05 5.7 0.15413
C. Orphan GPCRs GPR37 38.3 9.46E−08 p < 0.05 −40.5 8.39E−09 p < 0.05 −27.0 0.00003 p < 0.05
GPRC5B 24.6 6.13E−06 P < 0.05 −38.3 2.94E−09 p < 0.05 −30.3 0.00004 p < 0.05
GPR56 7.2 0.161404 −15.9 0.00261 p < 0.05 −14.9 0.00298
GPR125 −8.1 0.088684 −11.5 0.011594 p < 0.05 −0.3 0.94843
The GPLS expression percent change differences (% change) by cohort for genes that met FDR in Cohort A or B. Blank FDR cells indicated those genes did not
pass FDR.
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FIGURE 1 | Dysregulation of genes involved in cAMP- and
phosphatidylinositol signaling pathways in brain tissue from patients
with BPD and MDD. The figure summarizes differentially expressed genes
regulating signaling pathways using second messengers of cAMP (A,B) and
phosphatidylinositol (C,D) in brain tissue from BPD (A,C) and MDD (B,D)
compared to control subjects. The differentially expressed genes are denoted
in italic and bold. (A) shows increased expression of transcripts related to
suppression of cAMP mediated signaling in BPD. (B) shows decreased
expression of transcripts related to suppression of cAMP mediated signaling
in MDD. (C) shows altered expression of transcripts related to
phosphatidylinositol mediated signaling in BPD. (D) shows altered expression
of transcripts related to phosphatidylinositol mediated signaling in MDD.
GNAI1, G protein alpha inhibiting activity 1; RGS20, Regulator of G-protein
signaling 20; PDE1A, Phosphodiesterase 1A; PDE8A, Phosphodiesterase 8A;
PKIA, Protein kinase A inhibitor alpha; PPP1CA, Protein phosphatase 1,
catalytic alpha; PPP1R3C, Protein phosphatase 1, regulatory 3C; INPP5F,
Inositol polyphosphate-5-phosphatase F; ITPKB, Inositol 1,4,5-trisphosphate
3-kinase B; INPP1, Inositol polyphosphate-1-phosphatase; CDS1,
CDP-diacylglycerol synthase 1; PIK3C2A, Phosphoinositide-3-kinase catalytic
2A; PIK3C2B, Phosphoinositide-3-kinase catalytic 2B; PIK3R1,
Phosphoinositide-3-kinase regulatory 1; PRKCI, Protein kinase C iota; ITPR1,
Inositol 1,4,5-triphosphate receptor 1; PRKCB1, Protein kinase C beta 1; NPY,
Neuropeptide Y; NPY1R, Neuropeptide Y receptor Y1; NTSR2, Neurotensin
receptor 2; EDNRB, Endothelin receptor type B; GRM3, Metabotropic
Glutamate receptor 3; EDG1, Endothelial differentiation GPCR 1; EDG2,
Endothelial differentiation GPCR 2.
In contrast, of those genes that repressed cAMP signaling activ-
ity in MDD (Figure 1B and Table 2) there was only one gene
(PDE8A) differentially expressed, hence this signaling pathway
was not over-represented (p > 0.05).
Gs/Gi -coupled GPCRs
Significant increases of NPY and NPY1R mRNA expression were
found in BPD in ACC. GRM3 expression was also increased in
ACC of BPD patients. Gi/G12-linked EDG2 was increased in ACC
of BPD, while Gi-linked EDG1 was decreased in ACC of MDD.
EDG1 and EDG2 regulate neuronal and glial functions, including
neurite retraction, neurogenesis, and axonal guidance (Takuwa
et al., 2002).
G proteins
Our data showed an increase of GNAI1 in the ACC of BPD, but
no change in GNAI1 expression in the DLPFC of BPD. Consistent
with our findings in DLPFC, immunoreactivity and functional
activity of Gi protein is not altered in the frontal cortex of BPD
(Young et al., 1993; Friedman and Wang, 1996). RGS20 was
significantly decreased in ACC of MDD cases.
Adenylate cyclase and protein kinase A
Expression levels of transcripts coding adenylate cyclases and
cAMP-dependent protein kinases (PKAs) were not altered in BPD
and MDD compared with controls in our study, which is con-
sistent with a previous study (Chang et al., 2003). The reported
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dysregulation in functional activities of adenylate cyclase and PKA
(Gould and Manji, 2002) may not be due to alterations at the
transcript level in the brain cortices.
Phosphatidylinositol signaling pathway
The phosphatidylinositol (PI) signaling pathway related genes
which were differentially expressed in ACC of BPD patients are
shown in Figure 1C and are summarized Table 2. The group of
phosphatidylinositol 3-kinases was significantly over-represented
in BPD based on a hypergeometric distribution (p = 0.042;
q = 0.36).
The PI signaling pathway related genes which were differen-
tially expressed in ACC of MDD patients compared with controls
are summarized in Figure 1D and Table 2. Since antidepressants
have been reported to affect PI signaling (Dwivedi et al., 2002;
Quintero et al., 2005), the potential effect of drug treatment on
the gene expression was considered. In cohort A, five MDD sub-
jects were prescribed SSRI at the time of death, whereas remaining
four MDD subjects were not prescribed and presumably not tak-
ing any SSRIs (Table 1). There were no significant differences in
mRNA expressions of PKCB1, ITPR1 and INPP5F between SSRI-
treated MDD and non-SSRI-treated MDD groups. However,
ITPKB mRNA expression was significantly lower in the non-
SSRI-treated MDD group than the SSRI-treated MDD group,
which suggests that SSRIs may attenuate the altered expression
in MDD toward levels observed in controls.
Gq-coupled GPCRs
NTSR2 was decreased in ACC of BPD. NTSR2mRNA and NTSR2
binding was reported to be down regulated in transgenic mice
over expressing corticotrophin releasing factor, which is linked
to anxiety, stress and depression (Peeters et al., 2004). EDNRB
was also decreased in ACC of MDD. Endothelin is known to be
a vasoconstrictor peptide as well as a neuromodulator regulat-
ing neuronal excitability. The data did not show any significant
differences in expression levels of Gq-linked monoamine GPCRs
(serotonin-2 receptors and adrenergic alpha-1 receptors), which
was consistent with previous microarray studies (Iwamoto et al.,
2004; Konradi et al., 2004; Sibille et al., 2004; Aston et al., 2005).
Lithium and second messengers
The microarray data highlighted several target molecules of
lithium treatment (Figure 1C). Lithium is known to block
INPP1 (inositol polyphosphate-1-phosphatase) enzyme activ-
ity, and INPP1 mRNA expression was increased in ACC of
BPD. Among the 6 BPD subjects, 3 BPD subjects treated with
lithium at the time of death showed lower signal intensi-
ties for INPP1 and PIK3C2B compared with remaining non-
lithium treated BPD subjects, although the difference did not
reach significant changes. There is a modest genetic asso-
ciation between INPP1 and sensitivity to lithium treatment
(Steen et al., 1998; Serretti, 2002). A second activity of
lithium is activation of phosphatidylinositol 3-kinases and reg-
ulation of glycogen synthesis kinase 3 beta (GSK3B) activity
(Sinha et al., 2005).
For MDD subjects, the mRNA expression of PKCB1, ITPR1,
and INPP5F were increased in ACC, while ITPKB mRNA was
decreased (Figure 1D). PKCB1 and ITPR1 are receptors for
diacylglycerol (DG) and inositol 1, 4, 5-triphosphate (ITP),
respectively, both of which are intracellular second messen-
gers produced by PLC-beta through a Gq protein-dependent
mechanism, while INPP5F and ITPKB metabolize ITP in a
signal-terminating reaction. Previous reports suggest decreased
PLC-beta activity in depressed patients (Pandey et al., 1997; Frey
et al., 1998; Moore et al., 1999), and over expressed PKCB1 may
down regulate PLC-beta activity (Pachter et al., 1992). The alter-
ations in expression levels of the molecules interacting with DG
and ITP may reflect functional impairments of Gq and PLC-beta
in MDD.
ORPHAN G PROTEIN-COUPLED RECEPTORS
The two GPCRs that showed the most consistent differential
expression patterns through both mood disorder analyses were
GPCR family C, group 5, member B (GPRC5B) and G protein-
coupled receptor 37 (GPR37)as shown in Table 2 and validated by
QPCR (Table 3). GPRC5B was significantly increased in ACC of
BPD patients and in DLPFC of BPD. GPR37 was also significantly
increased in ACC of BPD. GPRC5B was significantly decreased in
ACC and DLPFC of MDD patients.
REAL TIME QUANTITATIVE PCR
We followed up on results primarily that met FDR in cohort
A for BPD, and both Cohorts A and B for MDD, except for
RGS20, which we followed up based upon Cohort A meet-
ing FDR while Cohort B met uncorrected p-value significance
only. Nine GPLS transcripts were selected for validation, five for
BPD and four for MDD. The qPCR results showed 100% con-
cordance between qPCR and microarray fold change for BPD
in ACC (Table 3) and 4/5 transcripts were statistically signifi-
cant. Four GPLS related transcripts showed 100% concordance
between qPCR and microarray fold change for MDD in ACC
(Table 3) and 4/4 transcripts were statistically significant. NPY,
GPRC5B, GPR37, and INPP1 were significantly increased in ACC
of BPD, whereas GPRC5B, GPR37, RGS20, and PPP1R3C were
significantly decreased in the ACC of MDD.
In situ HYBRIDIZATION HISTOCHEMISTRY
GPR37 mRNA was preferentially expressed in subcortical white
matter. The sense probe hybridization signal showed background
signal. GPR37 mRNA expression in subcortical white matter was
higher in ACC of both of the BPD subjects compared to both of
the control subjects, whereas GPR37mRNA expression in subcor-
tical white matter was lower in ACC of both of the MDD subjects
compared to both of the control subjects (Figure 2). This prelimi-
nary data suggests that the significant differential microarray and
QPCR expressions of GPR37 between BPD/MDD and controls
may reflect altered expression levels of GPR37 mRNA in subcor-
tical white matter. mRNA expression of GPRC5B was not specific
in ACC samples tested, most likely due to strong background
hybridization issues.
DISCUSSION
The results of the study of GPLS transcriptional profiling
showed differences in BPD and MDD in both the cAMP- and
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Table 3 | Quantitative PCR data summary of anterior cingulate cortex (ACC) genes in BPD or MDD that showed altered expression compared to
the control group.
Symbol Gene name BPD vs. Control MDD vs. Control
Microarray %
change
Unadjusted
p-value
qPCR %
change
Unadjusted
p-value
Microarray %
change
Cohort B
Unadjusted
p-value
qPCR %
change
Unadjusted
p-value
SST Somatostatin 22.1 5.4 E−05** 10.1 p > 0.05 −6.5 0.108 NT NT
GPRC5B G protein-coupled
receptor C−5−B
24.6 6.13E−06** 46.8 p < 0.05 −30.3 0.00004** −54.0 p < 0.01
INPP1 Inositol
polyphosphate-1-
phosphatase
24.9 9.4E−06** 21.7 p < 0.05 −7.4 0.04372 NT NT
NPY Neuropeptide Y 33.0 1.48E−06** 37.6 p < 0.05 3.6 0.54313 NT NT
GPR37 G protein-coupled
receptor 37
38.3 9.46E−08** 54.1 p < 0.05 −27.0 0.00003** −62.7 p < 0.05
RGS20 Regulator of
G-protein signaling
20
15.6 0.005 NT NT −29.2# 5.85E−06**# −36.9 p < 0.01
PPP1R3C Protein phosphatase
1 regulatory subunit
3C
−15.4 0.0005 NT NT −21.4 0.00006** −46.1 p < 0.01
These genes selected for qPCR analyses met the criteria of false discovery rate multiple testing correction at the level of accepting 5% false positives and percentage
change greater than 20% in the anterior cingulate cortex microarray results in Cohort A for BPD, and in Cohort B for MDD. The qPCR analyses were run for seven
representative GPLS selected from ligand peptides, GPCRs, and G protein regulators.
NT, not tested by qPCR as did not meet criteria of 20% change and passing FDR by microarray.
**Indicates a gene that passed FDR.
#RGS20 values shown are for Cohort A.
FIGURE 2 | In situ hybridization images of GPR37mRNA in representative
BPD, MDD and control subjects. GPR37 mRNA is preferentially expressed in
subcortical white matter. Among six layers of cortical gray matter, GPR37
expression in deeper layers (V–VI) is relatively higher than in superficial layer
(I–III). Expression levels in GPR37 is increased in the BPD subjects, and
decreased in MDD subjects in subcortical white matter in anterior cingulate
cortex tissue, compared to control subjects. WM, Subcortical white matter;
BPD, Bipolar disorder; MDD, Major depressive disorder.
phosphatidylinositol signaling pathways. The following pattern of
alterations in GPLS were observed:
(1) Transcriptional levels of molecules acting as neg-
ative regulators in cAMP signaling pathways are
increased in BPD and decreased in MDD, which may
compensate for the activated cAMP signaling activ-
ity in BPD and the blunted cAMP signaling activity
in MDD,
(2) Expression of PRKCB1, ITPR1, INPP5F, and ITPKB were
altered in MDD, which may reflect functional impairments
of Gq and PLC-beta in the disorder,
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(3) Expression of INPP1 and phosphatidylinositol 3-kinases
were altered in BPD suggesting that these molecules may be
involved in both the pathophysiology and the mechanism(s)
of action of lithium treatment of BPD, and
(4) Two orphan GPCR genes, GPRC5B and GPR37, showed sig-
nificant increases in ACC of BPD, and decreases in ACC and
DLPFC of MDD.
ORPHAN G PROTEIN-COUPLED RECEPTORS
Among all GPCRs, the most consistent differential expression
patterns were observed for GPRC5B and GPR37. GPRC5B was
significantly increased in ACC and DLPFC of BPD, while signif-
icantly decreased in ACC and DLPFC of MDD patients. GPR37
was significantly increased in ACC of BPD, and significantly
decreased in ACC and DLPFC of MDD patients. The consistent
cortical alterations of GPRC5B and GPR37 expression observed
in MDD patients suggest a role of these genes in the pathophys-
iology of MDD. So far, these two orphan GPCRs have not been
highlighted as candidate susceptible genes for BPD and MDD,
however previous microarray data supports decrease of both
GPRC5B and GPR37 expressions in MDD patients (Aston et al.,
2005). Our microarray data strongly suggests these genes might
be involved in the pathophysiology of the disorders. GPR37 and
GPRC5B are both implicated in Parkinson’s disease (Marazziti
et al., 2009, 2011), which has depression as one premorbid
indicator, possibly concomitant with brain neurodegenerative
processes.
GPR37 appears to facilitate dopamine neurotransmission, and
reductions in brain GPR37 leads to behavioral alterations in con-
ditioned place preferences to reinforcements such as cocaine or
amphetamine (Marazziti et al., 2011). GPR37 (Class A receptor)
contains a large extracellular domain which led to speculations
that the ligand of this receptor may be a protein rather than a
peptide (Leng et al., 1999). GPR37 is predominantly expressed
in the brain (Zeng et al., 1997; Marazziti et al., 1998; Leng et al.,
1999), especially in glial cells of the fiber tracts, Purkinje cells in
cerebellum, neuronal cells in hippocampus CA3 region and sub-
stantianigra (Zeng et al., 1997; Imai et al., 2001). GPR37 has been
shown to be involved in the dopaminergic system (Imai et al.,
2001, 2002;Marazziti et al., 2004). GPR37 is also called Pael recep-
tor (PAELR). Unfolded PAELR is a substrate of E3 ubiquitin ligase
Parkin, and accumulation of Pael-R in the endoplasmic reticu-
lum (ER) of dopaminergic neurons is considered to induce ER
stress leading to neurodegeneration in Parkinson disease (Imai
et al., 2002). Gpr37−/− mice shows reduced striatal dopamine
content and enhanced amphetamine sensitivity (Marazziti et al.,
2004). Our ISH data suggest that the predominant expression
of GPR37 mRNA in ACC occurred mainly in subcortical white
matter. GPR37 is a substrate of parkin (PARK2), and its insolu-
ble aggregates accumulate in brain tissue samples of Parkinson’s
disease patients, AKA PaelR (Marazziti et al., 2009).
GPRC5B is phylogenetically classified into a type C GPCR,
however, in contrast to other type C genes, GPRC5B has a short
N terminal domain (Brauner-Osborne and Krogsgaard-Larsen,
2000). QPCR based expression analysis shows GPRC5B is pre-
dominantly expressed in brain, with most abundant expression
in neuronal cells of caudate, putamen, substantia nigra, thalamus
and hippocampus and glial cells of the fiber tracts (Brauner-
Osborne and Krogsgaard-Larsen, 2000; Robbins et al., 2002).
Behavioral abnormalities exist in GPRC5B knock-outs, decreased
spontaneous locomotor activity, and decreased responses to a new
environment (Sano et al., 2011).
The expression patterns of GPRC5B and GPR37 suggest that
both of these orphan GPCRs may be involved in various cellular
functional activities in the brain including neuronal and glial cells.
Functional characterization of GPRC5B and GPR37 may pro-
vide new insights into the pathophysiology of mood disorder, and
potential novel strategies for developing methods for diagnoses
and treatment of the disorders.
There are limitations to this post-mortem study of GPLS path-
way expression. We conducted seven qPCR validations of genes
that passed FDR, and although a small number, those genes did
represent large enough percent fold changes to validate by qPCR.
Other technologies could be used that are less costly, such as
Nanostring or Fluidigm for additional validation studies, which
are now being conducted on larger sample sizes. In addition,
we do not have confirmed toxicological analysis of all drugs of
abuse and therapeutic levels to rule out these effects in explaining
case—control expression differences. Finally, we are aware that
small residual agonal effects might exist that are not corrected in
this analysis, however we did confirm that the present data pre-
sented in Table 2, was not due to the effects of age or pH on gene
expression.
SUMMARY
This study highlights transcript profile differences in GPLS path-
ways in both BPD and MDD. Since sample sizes were low, we
also used a second independent cohort in the case of MDD
gene expression to check concordance. We relied upon dupli-
cate microarray analysis at independent laboratories, and used
gene expression values that were significantly correlated between
sites, and employed FDR to select genes to advance for qPCR
experimental validations.
The disturbances observed in cAMP- and
phosphatidylinositol- pathway regulation may be due to
differential activation of individual GPCRs and individual
differences in ligand- receptor sensitivity, suggesting that func-
tional and genetic characterization of these candidate genes
may provide further understanding of the pathophysiology
of mood disorders. Further studies will also be required to
investigate additional GPCR signaling pathway features such as
receptor phosphorylation, beta-arrestin recruitment, receptor
desensitization, and internalization, and beta-gamma mediated
signaling. The results of the present study suggest that future
functional activity studies of the GPLS pathways would elucidate
the relationship of the observed transcript changes to protein
levels and functional outcomes in mood disorders.
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